NSCLC (Non-small Cell Lung Cancer) research hub
4 indexed studies · 4 currently recruiting
- recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
This study is testing a new medicine called BH-30643 for a type of advanced lung cancer. It aims to see if it's safe, how well it works, and what dose is best for people with specific gene changes in their cancer.
United States · Australia · Canada - not yet recruiting
Immune-Marker Platform for Patients With Advanced Lung Cancer
This study looks at how your body's immune system and certain markers in your tumour relate to how well treatments work for advanced lung cancer. It helps doctors understand how to give better care.
Germany - recruiting
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
This study looks at how quick tests on blood or tissue samples help doctors choose treatments for people with advanced lung cancer. It collects real-world information on treatments and how patients feel, aiming to improve future care.
France · Italy · Spain